Mapi-Pharma Filed, US Offering, Removed, Nasdaq: MAPI

Developing extended-release formulations of existing drugs and generics.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a clinical stage pharmaceutical company, engaged in the development of improved extended-release versions of existing commercially successful products, which we refer to as life cycle management, or LCM products, that target large markets, as well as high-barrier to entry and high-added value generic drugs.
more less
IPO News for Mapi-Pharma
more
IPO Data
IPO File Date 03/26/2014
Offer Price
Price Range $15.00 - $17.00
Offer Shares (mm) 3.1
Deal Size ($mm) $50
IPO Data
IPO Date
Offer Price
Price Range $15.00 - $17.00
Offer Shares (mm) 3.1
Deal Size ($mm) $50
Underwriters
more
Company Data
Headquarters Ness Ziona, Israel
Founded 2008
Employees 23
Website www.mapi-pharma.com